rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

60 Degrees Pharmaceuticals, Inc.

SXTP · Nasdaq

Health CareBiotechnologyNot moving yet

SXTP stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 41.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$40K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
8 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$107KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Geoffrey S. DowPresident and CEObought7,350at $1.3812 Jun 2026filed 15 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders8+1 on the quarter
New · exited3 · 2
Reported value$615K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Kathmere Capital Management, LLCadded · filed 29 Jul 2026265,100$467K+120,417+83.2%
CITADEL ADVISORS LLCnew · filed 14 Aug 202622,362$39K+22,362
XTX Topco Ltdnew · filed 14 Aug 202617,639$31K+17,639
Kovack Advisors, Inc.new · filed 29 Jul 202615,000$26K+15,000
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202614,551$26K-1,744−10.7%
UBS Group AGreduced · filed 13 Aug 202613,592$24K-17,818−56.7%
BARCLAYS PLCreduced · filed 14 Aug 20261,052$1,851-804−43.3%
OSAIC HOLDINGS, INC.unchanged · filed 14 Aug 202625$4400.0%
30 Sep 2023 – 30 Jun 2026
468Sep 23Jun 24Mar 25Sep 25Jun 26

Everyone who traded it

Geoffrey S. Dow Company insiderPresident and CEO · last 12 Jun 202611 · 0
Cheryl Xu Company insiderDirector · last 3 Jun 20256 · 0
Kristen Landon Company insiderChief Operating Officer · last 17 Jan 20250 · 0
Tyrone Miller Company insiderCFO · last 17 Jan 20250 · 0
Charles W. Allen Company insiderDirector · last 16 May 20240 · 0
Paul Field Company insiderDirector · last 16 May 20240 · 0
Stephen Toovey Company insiderDirector · last 16 May 20240 · 0
Therapeutics International Sa Knight Company insiderOther · last 28 Jul 20230 · 0

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202522.3%
Operating profit marginFY 2025 · to 31 Dec 2025-772%
Free cash flow marginFY 2025 · to 31 Dec 2025-695%
Debt to equityFY 2025 · to 31 Dec 20250.05×
Research spendFY 2025 · to 31 Dec 2025209%
Share count trendFY 2025 · to 30 Mar 2026127%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.5M
Free cash flowFY 2025 · to 31 Dec 2025−$7.0M

Analyst forecasts

No analyst forecasts yet.